Low-grade systemic inflammation in patients with long COVID: The role of imbalance of endotoxin-releasing systems and vasoconstrictor markers

Background. Currently, the pathophysiological mechanisms of acute damage to organs and systems caused by coronavirus infection have been studied quite fully, but the mechanisms underlying the clinical manifestations of long COVID have not yet been accurately described. The mechanisms of persistence of a number of symptoms in patients who have had COVID-19 and the role of systemic inflammation and endotoxemia markers in it remain a understudied aspect and a promising direction for further studying.

The aim of the study. To assess the markers of systemic inflammation, endotoxin-releasing systems, intestinal permeability and endothelial dysfunction in patients with long COVID at the stage of health resort treatment.

Methods. The study included 32 patients who had recovered from coronavirus infection and were undergoing health resort treatment in the pulmonology department of the I.M. Sechenov Academic Research Institute for Physical Therapy, Medical Climatology and Rehabilitation. We also selected a control group (n = 20). All patients underwent peripheral blood analysis to detect the levels of markers of systemic inflammation, endotoxin-releasing systems, intestinal permeability, endothelial dysfunction and vasoconstrictor agents: C-reactive protein (CRP), lipopolysaccharide-binding protein (LPB), tissue-type plasminogen activator (tPA), zonulin, bactericidal/ permeability-increasing protein (BPI), vasopressors of angiotensin 2 and endothelin (EDN1).

Results. Patients who had recovered from coronavirus infection had a statistically significant increase in the levels of CRP (3.4 [2.56; 4.0] mg/l), LBP (18.46 [14.0; 25.5] ng/ml), tPA (0.07 [0.02; 0.32] ng/ml), angiotensin 2 (133.3 [63.0; 503.7] pg/ml) and a decrease in the level of BPI (1576 [276; 3588] pg/ml) (p < 0.05).

Conclusion. A statistically significant increase in markers of systemic inflammation, endotoxinemia, and vasoconstrictor agents in patients with long COVID indicates an imbalance in endotoxin-binding and endotoxin-releasing systems in patients who have had coronavirus infection. Further study of the described markers is necessary to improve approaches to long-term personalized therapy for this category of patients.

1. Lai YJ, Liu SH, Manachevakul S, Lee TA, Kuo CT, Bello D. Biomarkers in long COVID-19: A systematic review. Front Med (Lausanne). 2023; 20(10): 1085988. doi: 10.3389/fmed.2023.1085988

2. Soumya RS, Unni TG, Raghu KG. Impact of COVID-19 on the cardiovascular system: A review of available reports. Cardiovasc Drugs Ther. 2021; 35(3): 411-425. doi: 10.1007/s10557020-07073-y

3. Smith P, Proesmans K, Van Cauteren D, Demarest S, Drieskens S, De Pauw R, et al. Post COVID-19 condition and its physical, mental and social implications: protocol of a 2-year longitudinal cohort study in the Belgian adult population. Arch Public Health. 2022; 80(151): 151. doi: 10.1186/s13690-022-00906-2

4. Michelen M, Manoharan L, Elkheir N, Cheng V, Dagens A, Hastie C, et al. Characterising long COVID: A living systematic review. BMJ Glob Health. 2021; 6(9): e005427. doi: 10.1136/bmjgh-2021-005427

5. Patel U, Malik P, Mehta D, Shah D, Kelkar R, Pinto C, et al. Early epidemiological indicators, outcomes, and interventions of COVID-19 pandemic: A systematic review. J Glob Health. 2020; 10(2): 020506. doi: 10.7189/jogh.10.020506

6. Maamar M, Artime A, Pariente E, Fierro P, Ruiz Y, Gutiérrez S, et al. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: A cross-sectional study. Curr Med Res Opin. 2022; 38(6): 901-909. doi: 10.1080/03007995.2022.2 042991

7. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, et al. 1-year outcomes in hospital survivors with COVID-19: A longitudinal cohort study. Lancet. 2022; 398(10302): 747-758. doi: 10.1016/S0140-6736(21)01755-4

8. Teixeira PC, Dorneles GP, Santana Filho PC, da Silva IM, Schipper LL, et al. Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients. Int Immunopharmacol. 2021; 100(12): 108125. doi: 10.1016/j.intimp.2021.108125

9. Al-Ani B, ShamsEldeen AM, Kamar SS, Haidara MA, AlHashem F, Alshahrani MY, et al. Lipopolysaccharide induces acute lung injury and alveolar haemorrhage in association with the cytokine storm, coagulopathy and AT1R/JAK/STAT augmentation in a rat model that mimics moderate and severe Covid-19 pathology. Clin Exp Pharmacol Physiol. 2022; 49(4): 483-491. doi: 10.1111/1440-1681.13620

10. Samsudin F, Raghuvamsi P, Petruk G, Puthia M, Petrlova J, MacAry P, et al. SARS-CoV-2 spike protein as a bacterial lipopolysaccharide delivery system in an overzealous inflammatory cascade. J Mol Cell Biol. 2022; 14(9): mjac058. doi: 10.1093/jmcb/ mjac058

11. Yatskov IA, Beloglazov VA, Kubyshkin AV, Nikolaeva AP, Zyablitskaya EYu, Kunitskaya YuE, et al. Lipopolysaccharidebinding protein and presepsin in patients with SARS-CoV-2 viral lung disease in the Republic of Crimea. Pulmonologiya. 2022; 32(2): 162-170. (In Russ.). doi: 10.18093/0869-0189-202232-2-162-170

12. Xu Sw, Ilyas I, Weng JP. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol Sin. 2023; 44(11): 695-709. doi: 10.1038/s41401-022-00998-0

13. Ciaglia E, Lopardo V, Montella F, Sellitto C, Manzo V, De Bellis E, et al. BPIFB4 circulating levels and its prognostic relevance in COVID-19. J Gerontol A Biol Sci Med Sci. 2021; 76(10): 1775-1783. doi: 10.1093/gerona/glab208

14. Beamer LJ, Carroll SF, Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 1997; 276(5320): 1861-1866. doi: 10.1126/ science.276.5320.1861

15. Tsounis EP, Triantos C, Konstantakis C, Marangos M, Assimakopoulos SF. Intestinal barrier dysfunction as a key driver of severe COVID-19. World J Virol. 2023; 12(2): 68-90. doi: 10.5501/wjv.v12.i2.68

16. Okuyucu M, Yalcin Kehribar D, Çapraz M, Çapraz A, Arslan M, Çelik ZB, et al. The relationship between COVID-19 disease severity and zonulin levels. Cureus. 2022; 14(8): e28255. doi: 10.7759/cureus.28255

17. Mouchati C, Durieux JC, Zisis SN, Labbato D, Rodgers MA, Ailstock K, et al. Increase in gut permeability and oxidized LDL is associated with post-acute sequelae of SARS-CoV-2. Front Immunol. 2023; 14(2): 1182544. doi: 10.3389/fimmu.2023.1182544

18. Kar M. Vascular dysfunction and its cardiovascular consequences during and after COVID-19 infection: A narrative review. Vasc Health Risk Manag. 2022; 18(6): 105-112. doi: 10.2147/VHRM. S355410

19. Yin JX, Yang RF, Li S, Renshaw AO, Li YL, Schultz HD, et al. Mitochondria-produced superoxide mediates angiotensin IIinduced inhibition of neuronal potassium current. Am JPhysiol Cell Physiol. 2010; 298(11): 857-865. doi: 10.1152/ajpcell.00313.2009

20. Zhang Z, Dai W, Zhu W, Rodriguez M, Lund H, Xia Y, et al. Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19. Res Pract Thromb Haemost. 2023; 7(6): 102164. doi: 10.1016/j.rpth.2023.102164

21. Ling L, Yang J, Mars WM, Brian-Reeves W, Kebin H. Myeloidderived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-κB pathways. Am JPathol. 2014; 184(10): 2757-2767. doi: 10.1016/j.ajpath.2014.06.013

22. Dupuis J, Cernacek P, Tardif JC, Stewart DJ, Gosselin G, Dyrda I, et al. Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. Am Heart J. 1998; 135(4): 614-620. doi: 10.1016/s0002-8703(98)70276-5

23. Nabeh OA, Matter LM, Khattab MA, Esraa Menshawey. The possible implication of endothelin in the pathology of COVID19-induced pulmonary hypertension. Pulm Pharmacol Ther. 2021; 71(2):102082. doi: 10.1016/j.pupt.2021.102082

24. Neu U, Mainou BA. Virus interactions with bacteria: Partners in the infectious dance. PLoS Pathog. 2020; 16(2): e1008234. doi: 10.1371/journal.ppat.1008234